Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 2/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12459222 | 0.88 | MPO (0.41) | IDO1MPOAGXTLOXL2PTGS1 | |
| SCHEMBL27409142 | 0.83 | IDO1 (0.41) | IDO1MPOAGXTLOXL2SLC6A2 | |
| SCHEMBL2625769 | 0.82 | IDO1 (0.42) | IDO1AGXTPTGS1PTGS2SLC6A2 | |
| SCHEMBL12740308 | 0.82 | IDO1 (0.42) | IDO1AGXTPTGS1PTGS2SLC6A2 | |
| SCHEMBL109671 | 0.82 | IDO1 (0.65) | IDO1MPOAGXTLOXL2SLC6A2 | |
| SCHEMBL27594514 | 0.80 | IDO1 (0.39) | IDO1MPOAGXTLOXL2RIPK1 | |
| SCHEMBL27576202 | 0.80 | IDO1 (0.39) | IDO1MPOAGXTLOXL2SLC6A2 | |
| SCHEMBL13403327 | 0.78 | PTGS1 (0.42) | IDO1PTGS1PTGS2RBP4NR3C2 | |
| SCHEMBL27667516 | 0.77 | IDO1 (0.36) | IDO1MPOSLC6A2SLC6A4RIPK1 | |
| SCHEMBL2100552 | 0.76 | PTGDR2 (0.42) | RBP4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11433065-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20200222384-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2019-09-26 | — | — | US | disclosed |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8193182-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | IDO1 3369/4885MPO 2155/4885AGXT 2709/4885 |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | IDO1 4608/4885MPO 2592/4885AGXT 3519/4885 |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | IDO1 4649/4885MPO 3566/4885AGXT 3297/4885 |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | IDO1 3086/4885MPO 1791/4885AGXT 2471/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | IDO1 2953/4885MPO 1025/4885AGXT 1947/4885 |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | IDO1 3369/4885MPO 2155/4885AGXT 2709/4885 |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | IDO1 3369/4885MPO 2155/4885AGXT 2709/4885 |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | IDO1 4649/4885MPO 3566/4885AGXT 3297/4885 |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | IDO1 4776/4885MPO 3145/4885AGXT 2575/4885 |
| US-20200222384-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | IDO1 4649/4885MPO 3566/4885AGXT 3297/4885 |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | IDO1 3313/4885MPO 4487/4885AGXT 3715/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | IDO1 2002/4885MPO 4150/4885AGXT 3344/4885 |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | IDO1 4503/4885MPO 3774/4885AGXT 2525/4885 |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | IDO1 1795/4885MPO 2798/4885AGXT 2641/4885 |
| US-11433065-B2 | Certain chemical entities, compositions and methods | PIK3CA, AKT3, PIK3C2A | IDO1 4649/4885MPO 3566/4885AGXT 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.